Reduction in Use of Risperidone for Dementia in Australia Following Changed Guidelines

• Główni autorzy: Lisa M Kalisch Ellett (Autor), Anna K Moffat (Autor), Svetla Gadzhanova (Autor), Nicole L Pratt (Autor), Jemisha Apajee (Autor), Michael Woodward (Autor), Elizabeth E Roughead (Autor)
• Format: Książka
• Wydane: MDPI AG, 2019-07-01T00:00:00Z.
• Hasła przedmiotowe: article
• Dostęp online: Connect to this object online.

<b>Background:</b> Risperidone is the only antipsychotic approved in Australia for the management of the behavioural and psychological symptoms of dementia (BPSD). In June 2015, the Australian Government Therapeutic Goods Administration (TGA) amended the indication to restrict use in BPS...